Success Metrics

Clinical Success Rate
73.1%

Based on 19 completed trials

Completion Rate
73%(19/26)
Active Trials
11(27%)
Results Posted
111%(21 trials)
Terminated
7(17%)

Phase Distribution

Ph phase_3
17
41%
Ph phase_4
3
7%
Ph phase_1
4
10%
Ph phase_2
14
34%

Phase Distribution

4

Early Stage

14

Mid Stage

20

Late Stage

Phase Distribution38 total trials
Phase 1Safety & dosage
4(10.5%)
Phase 2Efficacy & side effects
14(36.8%)
Phase 3Large-scale testing
17(44.7%)
Phase 4Post-market surveillance
3(7.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

67.9%

19 of 28 finished

Non-Completion Rate

32.1%

9 ended early

Currently Active

11

trials recruiting

Total Trials

41

all time

Status Distribution
Active(12)
Completed(19)
Terminated(9)
Other(1)

Detailed Status

Completed19
Terminated7
Recruiting6
Active, not recruiting5
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
11
Success Rate
73.1%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (10.5%)
Phase 214 (36.8%)
Phase 317 (44.7%)
Phase 43 (7.9%)

Trials by Status

unknown12%
recruiting615%
active_not_recruiting512%
completed1946%
withdrawn25%
terminated717%
not_yet_recruiting12%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT07554495Phase 3

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Not Yet Recruiting
NCT07553182Phase 3

OLE Study With Filgotinib in JIA

Recruiting
NCT06865417Phase 3

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Recruiting
NCT05817942

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Active Not Recruiting
NCT06222034Phase 1

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Recruiting
NCT05323591

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Active Not Recruiting
NCT05785611Phase 3

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Active Not Recruiting
NCT04871919

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Active Not Recruiting
NCT04985435Phase 4

Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)

Recruiting
NCT03025308Phase 3

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Completed
NCT02914535Phase 3

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Active Not Recruiting
NCT03201445Phase 2

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Terminated
NCT05479058Phase 3

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Terminated
NCT06527534Phase 4

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Recruiting
NCT02914600Phase 3

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Terminated
NCT06285539Phase 2

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Recruiting
NCT02065700Phase 2

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

Completed
NCT03926195Phase 2

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Completed
NCT02914561Phase 3

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Completed
NCT06043739Phase 1

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Completed

Drug Details

Intervention Type
DRUG
Total Trials
41